Active	Status	Sponsor type	Region	Phase	Filter
22 Active 3 Inactive 25 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burgess, Melissa
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma	Recruiting	3	300	Canada, US, RoW	ADI PEG20, Pegargiminase, Placebo	Polaris Group	Soft Tissue Sarcoma	12/27	12/27
EZH-301, NCT04204941 / 2019-003648-55: Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021 May 2021 - May 2021: Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021	Recruiting	3	164	Europe, Canada, US, RoW	Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo	Epizyme, Inc.	Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma	01/29	01/30
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)	Active, not recruiting	2/3	360	Europe, Canada, US, RoW	Unesbulin, PTC596, Dacarbazine, DTIC, Placebo	PTC Therapeutics, PTC Therapeutics, Inc.	Leiomyosarcoma	06/24	06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors	Active, not recruiting	2/3	192	Europe, US, RoW	AL102, Placebo	Immunome, Inc.	Desmoid, Desmoid Tumor	10/25	10/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma	Active, not recruiting	1/2	15	US	YH001, Envafolimab, KN035, Doxorubicin	Tracon Pharmaceuticals Inc.	Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma	11/23	09/25
NCT04762602: A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations	Active, not recruiting	1	90	Europe, US	HMPL-306	Hutchmed	Isocitrate Dehydrogenase Gene Mutation	03/25	09/25
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study	Recruiting	1	250	Europe, Canada, US, RoW	ADP adoptive cell therapy	Adaptimmune	Neoplasms	04/32	04/32
Illar, Gwendolyn
NCT04762602: A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations	Active, not recruiting	1	90	Europe, US	HMPL-306	Hutchmed	Isocitrate Dehydrogenase Gene Mutation	03/25	09/25
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer	Terminated	1	31	US	XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin	Mersana Therapeutics, IQVIA Biotech, PSI CRO	Platinum-sensitive Ovarian Cancer (UPGRADE-A)	10/23	10/23